Abbott price target raised to $145 from $140 at BTIG

BTIG raised the firm’s price target on Abbott (ABT) to $145 from $140 and keeps a Buy rating on the shares after its Q1 earnings beat. The company reported a “solid” quarter and offered encouraging details on its tariff offsets and manufacturing flexibility, the analyst tells investors in a research note. A very large percent of the company’s U.S. sales come from U.S. products, and the management cited Libre as an example where its two manufacturing sites in the U.S. serve the U.S. market, the firm adds.